International Journal of Clinical Case Reports, 2025, Vol.15, No.5, 239-247 http://medscipublisher.com/index.php/ijmms 245 Gene therapy is also being tested. Adding SIRT3 just to the heart helped keep heart function steady after LPS. But when Sirt3 was blocked, heart function got worse (Peng et al., 2024). These studies show that boosting the SIRT3-FOXO3a pathway may be a promising way to treat SCM. 5.3 Unresolved research questions Although much has been discovered, several important questions remain. One is which lysine sites on FOXO3a are modified by SIRT3, as current studies give conflicting results. More precise tools, such as live-cell imaging and proteomics, are needed to identify the exact sites. Another gap is the complete set of genes FOXO3a activates in heart cells. While Catalase, SOD2, and Bnip3 are known targets, there are likely additional ones (Zhao and Liu, 2021). Other proteins may also affect this axis. For example, we don’t know if NF-κB, which becomes very active during infections, blocks FOXO3a from entering the nucleus. Or whether nitric oxide or ROS can directly damage SIRT3 (Qin et al., 2024). In real patients, we also need to ask: do SIRT3 activators affect the immune system’s ability to fight infections. Another challenge is that SIRT3 and FOXO3a are present in many tissues. Therefore, targeted delivery methods are needed to ensure they reach the intended site, reducing side effects in other organs. In addition, baseline levels of this axis vary among individuals, and its role may shift with different stages of SCM (Murugasamy et al., 2022; Trinh et al., 2024). Answering these questions will be important if we want to move this treatment approach into clinical use. 6 Conclusion and Outlook Septic cardiomyopathy (SCM) is still a major cause of death in people with sepsis. Its complex mechanisms make it hard to treat and study. In this review, we focused on the SIRT3-FOXO3a axis. This pathway helps keep mitochondria healthy and reduces oxidative stress. It offers a new way to look at how SCM develops and worsens. Many studies indicate that SIRT3 activates FOXO3a by deacetylation. Once activated, they jointly trigger genes that combat oxidative stress and restore mitochondrial function. This reduces ROS accumulation and preserves mitochondrial activity. Under stress conditions such as sepsis, this axis supports heart cell protection and sustains energy production. When this axis is not working-like when SIRT3 or FOXO3a levels drop in septic patients-mitochondria get damaged more easily, and heart function gets worse. But when the axis is turned back on, things improve. Antioxidant enzyme levels go up, mitochondria work better, and the heart pumps more strongly. These results give us useful clues for how to treat SCM. Looking ahead, treatments that target this axis may be helpful. New drugs that boost SIRT3 might help fix mitochondrial problems in sepsis. FOXO3a activators or stabilizers could also strengthen the cell’s own defense systems. Some researchers are testing combo treatments-like turning on both the SIRT3–FOXO3a axis and the Nrf2/AMPK pathways. These combinations may help control oxidation, metabolism, and inflammation all at once. Early animal tests show they may work well together. There are still problems to solve. We need drugs that are safe, work only in the right place, and are easy to give. But new advances in nanotech and gene therapy give hope. Tiny carriers could send SIRT3 mRNA or FOXO3a directly to the heart. This could boost the axis in heart cells without harming other parts of the body. Learning more about the SIRT3–FOXO3a axis helps us understand SCM better and gives us new ideas for treatment. Future work should bring together biology, drug research, and clinical trials. With continued teamwork and innovation, new therapies that target this axis could bring real hope to people with SCM-and maybe even save lives. The road to protecting the heart in sepsis is long, but this axis might help light the way. Acknowledgments Thanks to Dr. Xue in this project team for collecting and combing the literature during the study.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==